U.S. stock market update: Envoy Medical down 11.66%

U.S. Stock Market Midday Update Envoy Medical fell 11.66%, with increased trading volume. According to recent key news: On September 22, Envoy Medical announced the signing of a definitive agreement to issue and sell 1,908,402 shares at a price of $1.31 per share, and simultaneously issue and sell unregistered warrants to purchase up to 5,725,206 shares of Class A stock in a private placement. This news led to a decline in market confidence in the company's stock price, resulting in a significant drop. On September 23, Spark's AI analyst rated Envoy Medical's stock as neutral, noting the company's poor financial performance, negative profit margins, and high leverage, with technical indicators showing a bearish outlook and valuation metrics indicating poor profitability. These factors collectively contributed to a low stock rating, further exacerbating the stock price decline. In a forward-looking statement released on September 22, Envoy Medical mentioned that if risks materialize or assumptions are incorrect, actual results may differ significantly from expected results. This increased market uncertainty regarding the company's future performance, leading to weakened investor confidence. The industry trend is unfavorable, and market sentiment is low. Top Stocks by Trading Volume in the Industry Boston Scientific rose 1.07%. According to recent key news: On September 23, analyst Steed maintained a strong buy rating on Boston Scientific, with a target price of $125.85, representing a 29.70% upside from current levels. This optimistic analyst rating boosted market confidence, driving the stock price up. Data source: TipRanks. On September 22, Boston Scientific's stock price fell 1.22%, marking the lowest closing price since April 22, 2025. The stock has declined for 10 consecutive days, with a cumulative drop of 10.63%, setting a record for the longest losing streak in history. Market concerns about the company's short-term performance intensified, putting pressure on the stock price. Data source: Dow Jones Market Data, FactSet. No other significant news. The overall performance of the healthcare industry remains stable. Intuitive Surgical rose 0.97%, with a trading volume of $442 million. According to recent key news: On September 23, Intuitive Surgical had an annualized return of 19.12% over the past 15 years, outperforming the market by 6.67%. This long-term strong performance attracted investor attention, driving the stock price up. On September 23, analyst Steed rated Intuitive Surgical as "moderate buy," with a target price of $597.88. This positive analyst rating further boosted market confidence. On September 21, the market viewed Intuitive Surgical's current stock price pullback after a difficult period as making it a more attractive investment choice. Investors expressed optimism about its solid fundamentals and healthy growth prospects The overall performance of the healthcare industry is good, with significant capital inflow. Abbott fell 0.51%, with a trading volume of $360 million. According to recent key news: On September 21, market analysts pointed out that although Abbott is currently rated as "Moderate Buy," top analysts believe there are five stocks that are more worthy of purchase. This news led to a decline in investor confidence in Abbott, putting pressure on its stock price. On September 22, Abbott's FreeStyle Libre series products were considered a strong driver for the company's long-term development. The company's diversified business in pharmaceuticals, diagnostic equipment, and nutritional products further enhanced its operational capabilities. However, despite these positive factors, the market remains cautious about its short-term performance. On September 24, according to TipRanks data, analysts have a consensus rating of "Strong Buy" for Abbott, with a target price of $146.39, indicating a potential upside of 7.42% from the current level. Nevertheless, there are still concerns in the market regarding its short-term volatility. The healthcare sector has recently shown stable performance, with significant capital inflow. Stocks ranked among the top in industry market capitalization Stryker fell 1.20%. According to recent key news: On September 23, market analysts believe there are five stocks that are more worthy of purchase than Stryker, despite Stryker currently having a Moderate Buy rating among analysts, which led to a decline in investor confidence and a drop in its stock price. Data source: MarketBeat. On September 22, market analysts continued to recommend other stocks instead of Stryker, further weakening market confidence in Stryker and affecting its stock price. Data source: MarketBeat. Market analysts lack confidence in Stryker